JP2013071935A - Agglomerated material containing tinged shimotsuto extract powder - Google Patents
Agglomerated material containing tinged shimotsuto extract powder Download PDFInfo
- Publication number
- JP2013071935A JP2013071935A JP2011214749A JP2011214749A JP2013071935A JP 2013071935 A JP2013071935 A JP 2013071935A JP 2011214749 A JP2011214749 A JP 2011214749A JP 2011214749 A JP2011214749 A JP 2011214749A JP 2013071935 A JP2013071935 A JP 2013071935A
- Authority
- JP
- Japan
- Prior art keywords
- granulated product
- weight
- extract powder
- stearate
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 239000000843 powder Substances 0.000 title claims abstract description 45
- 239000000463 material Substances 0.000 title abstract 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229930006000 Sucrose Natural products 0.000 claims description 35
- 239000005720 sucrose Substances 0.000 claims description 35
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 34
- 239000008187 granular material Substances 0.000 claims description 33
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 32
- 239000000194 fatty acid Substances 0.000 claims description 32
- 229930195729 fatty acid Natural products 0.000 claims description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 32
- 235000019359 magnesium stearate Nutrition 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 28
- 238000000034 method Methods 0.000 description 21
- 239000000546 pharmaceutical excipient Substances 0.000 description 19
- 238000001035 drying Methods 0.000 description 14
- 241000411851 herbal medicine Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000000748 compression moulding Methods 0.000 description 7
- 238000007908 dry granulation Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000012676 herbal extract Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 3
- 244000000626 Daucus carota Species 0.000 description 3
- 235000002767 Daucus carota Nutrition 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000004503 fine granule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IIEJGTQVBJHMDL-UHFFFAOYSA-N 2-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-[2-oxo-2-[3-(sulfamoylamino)pyrrolidin-1-yl]ethyl]-1,3,4-oxadiazole Chemical compound C1CN(CC1NS(=O)(=O)N)C(=O)CC2=NN=C(O2)C3=CN=C(N=C3)NC4CC5=CC=CC=C5C4 IIEJGTQVBJHMDL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000219318 Amaranthus Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241001222097 Xenocypris argentea Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- AECIIQVDGKYLNI-VUAWYJOHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AECIIQVDGKYLNI-VUAWYJOHSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、加味四物湯エキス末を含む造粒物に関する。より詳細には、本発明は、製造時の成形性に優れ、良好な崩壊性を備える加味四物湯エキス末含有造粒物に関する。 The present invention relates to a granulated product containing a kamitsumonoyu extract powder. More specifically, the present invention relates to a granulated product containing a kamishitsuto extract powder having excellent moldability during production and good disintegration.
古来、生薬は漢方薬として使用されており、その漢方処方は、長年の経験の集積として多くの古典(万病回春、傷寒論、金匱要略等)に記載されている。しかしながら、古典に従って、生薬を切裁し、水で煎じて生薬中の成分を抽出した煎剤は、その独自の薬臭と呈味のために服用しづらいだけでなく、服用の度に調製しなければならないため、多くの手間と時間を要する。そこで、今日では、用時調製の手間を省け、服用し易い漢方製剤として、漢方薬エキス剤が利用されている。通常、漢方薬エキス剤は、切裁した生薬を、水やアルコール等の抽出溶媒で抽出し、この抽出液をそのまま又は濃縮、乾燥して漢方薬エキス末を得、これを製剤化して、種々の剤型(例えば、錠剤、カプセル剤、散剤、細粒剤、顆粒剤等)にする方法により製されている。 Traditionally, herbal medicines have been used as traditional Chinese medicines, and their prescriptions have been described in many classics (many disease recovery, wound cold theory, Jin Yong outline, etc.) as accumulated experience over many years. However, in accordance with the classics, decoction that is cut from herbal medicine and decocted with water to extract ingredients in herbal medicine is not only difficult to take due to its unique medicinal odor and taste, but also must be prepared each time it is taken. This requires a lot of work and time. Therefore, today, a herbal medicine extract is used as an easy-to-use Chinese medicine preparation that saves the trouble of preparation at the time of use. Usually, a herbal medicine extract is obtained by extracting a herbal medicine that has been cut out with an extraction solvent such as water or alcohol, and concentrating and drying the extract to obtain a herbal medicine extract powder. It is manufactured by a method of forming a mold (for example, tablet, capsule, powder, fine granule, granule, etc.).
従来、漢方薬エキス末を錠剤、顆粒剤、細粒剤等に製剤化する技術として、湿式造粒法と乾式造粒法が知られている。湿式造粒法は、溶媒を用いて混合、造粒をした後に乾燥を行って造粒物を得る製法であるが、溶媒を除去する際に高温加熱する必要があり、漢方薬エキス末に含まれる有効成分の損失が生じ得るという欠点があるため、一般的に漢方薬エキス末の製法には不向きと考えられている。一方、乾式造粒法は、混合、造粒の際に溶媒を利用しないため、高温加熱による有効成分の損失が生じないため、漢方薬エキス末の製法として適しており、従来、種々の漢方薬エキス末の製造に広く採用されている(例えば、非特許文献1、特許文献1等参照)。 Conventionally, a wet granulation method and a dry granulation method are known as techniques for formulating herbal extract powder into tablets, granules, fine granules and the like. The wet granulation method is a method for obtaining a granulated product by mixing and granulating with a solvent and then drying to obtain a granulated product, which requires heating at a high temperature when the solvent is removed, and is included in the herbal medicine extract powder Due to the disadvantage that active ingredients may be lost, it is generally considered unsuitable for the method of manufacturing Chinese herbal extract powder. On the other hand, the dry granulation method does not use a solvent during mixing and granulation, and therefore, there is no loss of active ingredients due to high-temperature heating. Therefore, the dry granulation method is suitable as a method for producing herbal extract powder. Are widely employed in the manufacture of non-patent documents (see, for example, Non-Patent Document 1, Patent Document 1, etc.).
しかしながら、漢方薬エキス末は、その種類によって、吸湿性や安定性等の物性が異なるため、全ての漢方薬エキス剤に対して共通する処方や造粒法が適用できるものではない。特に、加味四物湯エキス末は、非常に高い吸湿性を有し、しかも成形性が悪いという特有の性質があることが知られている。そのため、加味四物湯エキス末を乾式造粒法によって製剤化に供する場合には、従来の技術では、多量の賦形剤を添加してその吸湿性及び成形性を改善することが必要とされている。 However, since the Chinese herbal extract powder has different physical properties such as hygroscopicity and stability depending on the type, the common prescription and granulation method cannot be applied to all herbal medicine extracts. In particular, it is known that the Kamitsumonoyu extract powder has a very high hygroscopic property and a unique property that the moldability is poor. Therefore, in the case of using the Kamitsumonoto extract powder by dry granulation, it is necessary to add a large amount of excipients to improve its hygroscopicity and moldability in the conventional technique. ing.
しかしながら、加味四物湯エキス末に多量の賦形剤を添加して造粒すると、成形性の欠点を改善できても、多量の賦形剤を含むことに起因して生じる造粒物の崩壊時間の遅延が問題となる。 However, if a large amount of excipients is added to the Kamitsumonotsuto extract powder and granulated, the granulated material collapses due to the inclusion of a large amount of excipients, even though the defects in moldability can be improved. Time delay is a problem.
このように、従来技術では、製造時の成形性に優れ、良好な崩壊性を備える加味四物湯エキス末含有造粒物の製剤化技術が確立しておらず、当該造粒物の提供を実現できていないのが現状であった。 Thus, in the prior art, there is no formulation technology for a granulated product containing Kamitsuyuto extract powder that has excellent moldability at the time of manufacture and good disintegration, and the provision of the granulated product is not provided. The current situation was not realized.
本発明は、製造時の成形性に優れ、良好な崩壊性を備える加味四物湯エキス末含有造粒物を提供することを目的とする。 An object of the present invention is to provide a granulated product containing Kamitsuyuto extract powder that has excellent moldability during production and has good disintegration properties.
本発明者は、上記課題を解決すべく鋭意検討を行ったところ、驚くべきことに、加味四物湯エキス末とステアリン酸塩を併用して製剤化した加味四物湯エキス末含有造粒物は、製造時の成形性に優れ、良好な崩壊性を備え得ることを見出した。更に、上記成分と共にショ糖脂肪酸エステルを配合することによって、加味四物湯エキス末含有造粒物の崩壊性をより一層向上できることも見出した。本発明は、かかる知見に基づいて、更に検討を重ねることにより完成したものである。 The present inventor made extensive studies to solve the above problems. Surprisingly, a granulated product containing a kamitsuyuto extract powder formulated with a combination of a kamitsuyuto extract powder and a stearate. Has been found to be excellent in moldability during production and have good disintegrability. Furthermore, it has also been found that the disintegration property of the granulated product containing the Kamijoto extract powder can be further improved by blending sucrose fatty acid ester with the above components. The present invention has been completed by further studies based on this finding.
即ち、本発明は、下記に掲げる態様の造粒物を提供する。
項1.加味四物湯エキス末、及びステアリン酸塩を含有することを特徴とする、造粒物。
項2.ステアリン酸塩の含有量が、造粒物の総量当たり、2〜5重量%である、項1に記載の造粒物。
項3.ステアリン酸塩がステアリン酸マグネシウムである、項1又は2に記載の造粒物。
項4.更に、ショ糖脂肪酸エステルを含有する、項1〜3のいずれかに記載の造粒物。
項5.ショ糖脂肪酸エステルを構成する脂肪酸の炭素数が12〜22である、項4に記載の造粒物。
項6.ショ糖脂肪酸エステルのHLB値が10以上である、項4又は5に記載の造粒物。
項7.ステアリン酸塩1重量部当たり、ショ糖脂肪酸エステルが0.1〜5重量部の比率で含まれる、項4〜6の何れかに記載の造粒物。
That is, this invention provides the granulated material of the aspect hung up below.
Item 1. A granulated product comprising a kamitsumonoyu extract powder and a stearate.
Item 2. Item 2. The granulated product according to Item 1, wherein the content of stearate is 2 to 5% by weight based on the total amount of the granulated product.
Item 3. Item 3. The granulated product according to Item 1 or 2, wherein the stearate is magnesium stearate.
Item 4. Item 4. The granulated product according to any one of Items 1 to 3, further comprising a sucrose fatty acid ester.
Item 5. Item 5. The granulated product according to Item 4, wherein the fatty acid constituting the sucrose fatty acid ester has 12 to 22 carbon atoms.
Item 6. Item 6. The granulated product according to Item 4 or 5, wherein the sucrose fatty acid ester has an HLB value of 10 or more.
Item 7. Item 7. The granulated product according to any one of Items 4 to 6, wherein sucrose fatty acid ester is contained at a ratio of 0.1 to 5 parts by weight per 1 part by weight of stearate.
本発明の造粒物は、非常に高い吸湿性を備える加味四物湯エキス末を含みながら、製造時の成形性が格段に向上しており、造粒時に生じる製造ロスを抑制できるため、工業的製造において高い製造効率を実現することができる。 While the granulated product of the present invention contains the Kamitsuyuto extract powder having very high hygroscopicity, the moldability at the time of production is remarkably improved, and the production loss that occurs during granulation can be suppressed. High production efficiency can be realized in the production.
また、本発明の造粒物は、良好な崩壊性を備えており、服用後に、体内で加味四物湯エキス末の所望効果を有効に奏させることが可能になっている。 Moreover, the granulated product of the present invention has a good disintegration property, and after taking it, it is possible to effectively exhibit the desired effect of the Kamitsuyuto extract powder in the body.
本発明の造粒物は、加味四物湯エキス末、及びステアリン酸塩を含有することを特徴とする。以下、本発明について詳述する。 The granulated product of the present invention is characterized in that it contains a kamijoyuto extract powder and a stearate. Hereinafter, the present invention will be described in detail.
加味四物湯は、中国明時代の医書「万病回春」に記載されており、下肢の筋力低下、神経痛、関節の腫れや痛み、関節リウマチ、関節炎等を改善するために使用されることが多い処方である。加味四物湯は、当帰、川きゅう、芍薬、地黄、蒼朮、麦門冬、人参、牛膝、黄柏、五味子、黄連、知母、及び杜仲を含む混合生薬である。ここで、当帰とは、セリ科トウキの根;川きゅうとは、セリ科センキュウの根茎を湯通ししたもの;芍薬とは、ボタン科シャクヤク等の根;地黄とは、ゴマノハグサ科カヤジオウ等の根;蒼朮とは、キク科ホソバオケラ等の根;麦門冬とは、ユリ科ジャノヒゲ等の根;人参とは、ウコギ科オタネニンジンの根;牛膝とは、ヒユ科ヒナタイノコズチ等の根;黄柏とは、ミカン科キハダの皮を除いた根;五味子とは、マツブサ科チョウセンゴミシの果実;黄連とは、キンポウゲ科オウレン等の根茎;知母とは、ユリ科ハナスゲの根茎;杜仲とは、トチュウ科トチュウの樹皮である。また、加味四物湯に含まれる生薬の内、蒼朮は、白朮(キク科オケラの根茎)と置換又は併用されていてもよい。本発明において、加味四物湯に含まれる各生薬の混合比については、特に制限されないが、通常、重量比で、当帰2.5〜3、川きゅう2〜3、芍薬2〜3、地黄3〜8、蒼朮3(白朮の場合、2.5)、麦門冬2.5〜5、人参1.5〜2.5、牛膝1〜2.5、黄柏1.5、五味子1〜1.5、黄連1.5、知母1〜1.5、及び杜仲1.5〜2が挙げられる。 Kami-Yomono-to is described in the Chinese medical era “Manju Rejuvenated” and is often used to improve lower extremity muscle weakness, neuralgia, swelling and pain of joints, rheumatoid arthritis, arthritis, etc. It is a prescription. Kami Shimonoto is a mixed herbal medicine that includes Toki, Kawakyu, Shakuyaku, Ji-Huang, Sakai, Mumon-Winter, Ginseng, Beef-Knee, Jasmine, Gomi-ko, Huang Ren, My Mom, and Tochu. Here, Toki refers to the roots of the ciraceae sugar beet; Kawakyu refers to those obtained by blanching the rhizome of the ciraceae senkyu; glaze refers to the roots of the button family peonies;蒼朮 is the root of Asteraceae, such as Asteraceae; the roots of Lilyaceae janohige, etc .; the carrot is the root of Panax ginseng; the cow knee is the root of Amaranthus japonica, etc .; Is the roots excluding the citrus yellowfin skin; Gomiko is the fruit of the Chrysanthemum family ginseng; the yellow stem is the rhizome of the buttercup family Auren, etc .; It is the bark of the eucommia eucommia. In addition, among the herbal medicines contained in the Kami four hot waters, persimmon may be replaced or used in combination with birch (Asteraceae rhizome). In the present invention, the mixing ratio of each herbal medicine contained in the Kamitsu four-boiled water is not particularly limited, but usually 2.5 to 3 for the weight, 2 to 3 for the river, 2 to 3 for the glaze, and the ground yellow 3-8, cocoon 3 (2.5 in the case of white cocoon), baron winter 2.5-5, carrot 1.5-2.5, cow knee 1-2.5, jaundice 1.5, gomisiko 1 1.5, Huang Ren 1.5, known mothers 1-1.5, and Tonaka 1.5-2.
本発明に使用される加味四物湯エキス末とは、加味四物湯を抽出処理することにより得られる抽出液又はその濃縮液を、乾燥処理に供して得られる乾燥エキス粉末である。以下に、加味四物湯の抽出及び乾燥条件について説明する。 The “Kamitsu four hot water extract powder” used in the present invention is a dry extract powder obtained by subjecting an extract obtained by subjecting the Kami four hot water to an extraction treatment or a concentrated solution thereof to a drying treatment. Below, the extraction and drying conditions of Kamitsu four hot water will be described.
加味四物湯の抽出処理に使用される抽出溶媒としては、特に制限されないが、例えば、水、エタノール、酢酸及びこれらの混合液が挙げられる。 Although it does not restrict | limit especially as an extraction solvent used for the extraction process of Kamijomonoyu, For example, water, ethanol, an acetic acid, and these liquid mixture are mentioned.
加味四物湯の抽出条件としては、特に制限されないが、例えば、加味四物湯の総重量(乾燥重量換算)に対して、5〜25倍量、好ましくは10〜20倍量の抽出溶媒を加え、通常70〜100℃で1〜2時間インキュベートして加熱煎出する方法が挙げられる。 There are no particular restrictions on the extraction conditions for Kamitsumonoyu, but for example, 5 to 25 times, preferably 10 to 20 times the amount of extraction solvent is added to the total weight (in terms of dry weight) of Kamiyotoyu. In addition, there is usually a method of incubating at 70 to 100 ° C. for 1 to 2 hours to heat decoction.
斯して得られた加味四物湯抽出液について、濾過等により固形分を除去し、必要に応じて、濃縮した後に、乾燥処理に供される。加味四物湯の抽出液又はその濃縮液の乾燥方法としては、特に制限されず、例えば、スプレードライ、減圧濃縮乾燥、凍結乾燥等が挙げられる。これらの乾燥方法の中でも、スプレードライ法が好適である。 The thus-obtained Kamitsuyuto extract is subjected to a drying treatment after removing solids by filtration or the like and concentrating as necessary. A method for drying the extract of the Kamitsu four hot water or the concentrated solution thereof is not particularly limited, and examples thereof include spray drying, vacuum concentration drying, freeze drying, and the like. Among these drying methods, the spray drying method is preferable.
加味四物湯抽出液を乾燥処理(特に、スプレードライによる乾燥処理)に供する場合、加味四物湯抽出液に賦形剤を添加することが望ましい。このように賦形剤を添加することにより、乾燥時間を短縮すると共に、乾燥後の加味四物湯エキス末の吸湿性を低減させることも可能になる。加味四物湯抽出液の乾燥処理に際して添加される賦形剤としては、薬学的に許容されるものである限り、特に制限されず、例えば、無水ケイ酸、含水二酸化ケイ素、ケイ酸アルミニウム、ケイ酸アルミン酸マグネシウム、メタケイ酸アルミン酸マグネシウム、夕ルク、酸化チタン等の無機賦形剤;セルロース、カルボキシメチルセルロース、メチルセロース、ヒドロキシプロピルセルロース等のセルロース類;デンプン、ヒドロキシプロピルスターチ等のデンプン類;デキストリン、ゼラチン等が挙げられる。これらの賦形剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 In the case of subjecting the Kamitsumonoyu extract to a drying treatment (particularly, a drying treatment by spray drying), it is desirable to add an excipient to the Kamitsumonoyu extract. Thus, by adding an excipient | filler, while shortening drying time, it also becomes possible to reduce the hygroscopic property of the seasoned four hot water extract powder after drying. The excipient added during the drying process of the Kamitsumonoto extract is not particularly limited as long as it is pharmaceutically acceptable. For example, silicic anhydride, hydrous silicon dioxide, aluminum silicate, silica Inorganic excipients such as magnesium aluminate, magnesium aluminate, silica, titanium oxide, etc .; celluloses such as cellulose, carboxymethylcellulose, methylserose, hydroxypropylcellulose; starches such as starch and hydroxypropyl starch; dextrin, Examples include gelatin. These excipients may be used alone or in combination of two or more.
加味四物湯抽出液の乾燥処理に際して添加される賦形剤の量(即ち、加味四物湯エキス末に含まれる賦形剤量)としては、特に制限されるものではないが、例えば、加味四物湯抽出液の乾燥重量100重量部当たり、賦形剤が5〜70重量部、好ましくは20〜50重量部が挙げられる。 The amount of excipient added during the drying process of the Kamitsu Yotsuyu extract (that is, the amount of excipient contained in the Kamitsu Yotsuyu extract powder) is not particularly limited. The excipient is 5 to 70 parts by weight, preferably 20 to 50 parts by weight, per 100 parts by weight of the dry weight of the four-product hot water extract.
本発明の造粒物において、前記加味四物湯エキス末の含有量については、特に制限されないが、例えば、当該造粒物の総量当たり、加味四物湯エキス末の乾燥エキス量換算で、10〜85重量%、好ましくは20〜80重量%、更に好ましくは30〜70重量%が挙げられる。本明細書において、加味四物湯エキス末の乾燥エキス量とは、加味四物湯エキス末中の加味四物湯由来成分の量であり、例えば、加味四物湯エキス末に賦形剤が含まれている場合には、当該賦形剤含量を除いて換算される値である。 In the granulated product of the present invention, the content of the above-mentioned Kamitsuyuto extract powder is not particularly limited. For example, the total amount of the granulated product is 10 in terms of the dry extract of the Kamijotoyu extract powder. -85 weight%, Preferably it is 20-80 weight%, More preferably, 30-70 weight% is mentioned. In the present specification, the dry extract amount of the Kamitsumonoyu extract powder is the amount of components derived from the Kamitsumonoyu extract powder. When it is contained, it is a value converted by excluding the excipient content.
本発明の造粒物は、前記加味四物湯エキス末と共に、ステアリン酸塩を含有する。このようにステアリン酸塩を含むことにより、製造時の成形性を格段に向上させ、しかも良好な崩壊性を備えることが可能になる。 The granulated product of the present invention contains a stearate salt together with the above-mentioned Kamishitokuyu extract powder. Thus, by including a stearate, it becomes possible to improve the moldability at the time of manufacture remarkably and to have a good disintegration property.
本発明で使用されるステアリン酸塩としては、薬学的に許容されるものである限り、特に制限されず、例えば、ステアリン酸マグネシウム、ステアリン酸カルシウム、ステアリン酸アルミニウム、ステアリン酸亜鉛等が挙げられる。これらの中でも、製造時の成形性及び造粒物の崩壊性をより一層向上させるという観点から、好ましくはステアリン酸マグネシウムが挙げられる。 The stearate used in the present invention is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include magnesium stearate, calcium stearate, aluminum stearate, zinc stearate and the like. Among these, magnesium stearate is preferable from the viewpoint of further improving the moldability during production and the disintegration property of the granulated product.
本発明の造粒物において、ステアリン酸塩の含有量は、特に制限されないが、当該造粒物の総量当たり、2〜5重量%が好ましい。とりわけ、ステアリン酸塩の含有量が2.5〜5重量%を充足する場合、造粒物に優れた崩壊性を備えさせつつ、製造時の成形性を格段顕著に向上させることができるので、本発明におけるステアリン酸塩の含有量として好適である。なお、従来、医薬製剤において、ステアリン酸塩は滑沢剤として使用されているが、例えば、ステアリン酸マグネシウムは過剰添加または過剰混合により成形阻害や成形品の崩壊不良を引き起こすことから(津田恭介ら、医薬品開発基礎講座X“18製剤工学”170−173頁、地人書館(1971);砂田久一ら、打錠用顆粒に関する研究、PHARM TECH JAPAN,9,1139、(1993年)等参照)、0.1〜1重量%程度配合されるに留まっている。それに対して、本発明におけるステアリン酸塩の含有量は従来の配合量を遥かに超えており、従来の滑沢剤とは目的及び好適な含有量の双方の点で異なっている。 In the granulated product of the present invention, the content of stearate is not particularly limited, but is preferably 2 to 5% by weight based on the total amount of the granulated product. In particular, when the content of stearate satisfies 2.5 to 5% by weight, the moldability during production can be remarkably improved while providing excellent disintegration in the granulated product. It is suitable as the content of stearate in the present invention. Conventionally, stearates have been used as lubricants in pharmaceutical preparations. For example, magnesium stearate causes molding inhibition and poor collapse of molded products due to excessive addition or mixing (Tsuda Keisuke et al. (See Pharmaceutical Development Basic Course X “18 Formulation Engineering”, pages 170-173, Jinshokan (1971); Kuichi Sunada et al., Research on Granules for Tableting, PHARM TECH JAPAN, 9, 1139, (1993)) About 0.1 to 1% by weight is blended. On the other hand, the content of stearates in the present invention far exceeds conventional blending amounts, and differs from conventional lubricants in both the purpose and the preferred content.
本発明の造粒物において、加味四物湯エキス末に対するステアリン酸塩の比率としては、特に制限されないが、例えば、加味四物湯エキス末の乾燥エキス量換算1重量部に対して、ステアリン酸塩が0.01〜0.5重量部、好ましくは0.025〜0.5重量部、より好ましくは0.05〜0.5重量部、さらに好ましくは0.06〜0.5重量部、とくに好ましくは0.06〜0.25重量部が挙げられる。 In the granulated product of the present invention, the ratio of the stearate to the Kamitsumonoyu extract powder is not particularly limited. For example, the stearic acid is 1 part by weight in terms of the dry extract amount of the Kamijotoyu extract powder. 0.01 to 0.5 parts by weight of salt, preferably 0.025 to 0.5 parts by weight, more preferably 0.05 to 0.5 parts by weight, still more preferably 0.06 to 0.5 parts by weight, Particularly preferred is 0.06 to 0.25 parts by weight.
本発明の造粒物は、上記成分の他に、ショ糖脂肪酸エステルを含有することができる。ショ糖脂肪酸エステルを含有することによって、製造時の優れた成形性を保持しつつ、造粒物の崩壊性をより一層向上させることが可能になる。 The granulated product of the present invention can contain a sucrose fatty acid ester in addition to the above components. By containing the sucrose fatty acid ester, it is possible to further improve the disintegration property of the granulated product while maintaining excellent moldability during production.
本発明で使用されるショ糖脂肪酸エステルの種類については、特に制限されないが、例えば、ショ糖ラウリン酸エステル、ショ糖ミリスチン酸エステル、ショ糖パルミチン酸エステル、ショ糖ステアリン酸エステル、ショ糖アラキジン酸エステル、ショ糖ベヘニン酸エステル、ショ糖カプリン酸エステル、ショ糖パルミチン酸エステル、ショ糖オレイン酸エステル、ショ糖リノール酸エステル等が挙げられる。これらのショ糖脂肪酸エステルの中でも、造粒物の崩壊性をより一層向上させるという観点から、ショ糖脂肪酸エステルの構成脂肪酸が、好ましくは炭素数12〜22、更に好ましくは炭素数14〜20、特に好ましくは炭素数16〜18のものが挙げられる。 The type of sucrose fatty acid ester used in the present invention is not particularly limited. For example, sucrose laurate, sucrose myristic ester, sucrose palmitate, sucrose stearate, sucrose arachidic acid Examples thereof include sucrose behenic acid ester, sucrose capric acid ester, sucrose palmitic acid ester, sucrose oleic acid ester, and sucrose linoleic acid ester. Among these sucrose fatty acid esters, from the viewpoint of further improving the disintegration property of the granulated product, the constituent fatty acids of the sucrose fatty acid ester are preferably 12 to 22 carbon atoms, more preferably 14 to 20 carbon atoms, Particularly preferred are those having 16 to 18 carbon atoms.
また、本発明で使用されるショ糖脂肪酸エステルのHLB値としては、造粒物の崩壊性をより一層向上させるという観点から、好ましくは10以上、更に好ましくは11〜16が挙げられる。 Moreover, as an HLB value of the sucrose fatty acid ester used by this invention, from a viewpoint of improving the disintegrating property of a granulated material further, Preferably it is 10 or more, More preferably, 11-16 is mentioned.
本発明において、ショ糖脂肪酸エステルは1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 In this invention, sucrose fatty acid ester may be used individually by 1 type, and may be used in combination of 2 or more type.
本発明の造粒物にショ糖脂肪酸エステルを含有させる場合、前記ステアリン酸塩とショ糖脂肪酸エステルの比率については、特に制限されないが、造粒物の崩壊性をより一層向上させるという観点から、ステアリン酸塩1重量部当たり、ショ糖脂肪酸エステルが、好ましくは0.1〜5重量部、更に好ましくは0.25〜4重量部、特に好ましくは0.5〜3重量部が挙げられる。 When the sucrose fatty acid ester is contained in the granulated product of the present invention, the ratio of the stearate and the sucrose fatty acid ester is not particularly limited, but from the viewpoint of further improving the disintegration property of the granulated product, The amount of sucrose fatty acid ester is preferably 0.1 to 5 parts by weight, more preferably 0.25 to 4 parts by weight, and particularly preferably 0.5 to 3 parts by weight per 1 part by weight of stearate.
本発明の造粒物にショ糖脂肪酸エステルを含有させる場合、当該ショ糖脂肪酸エステルの含有量については、特に制限されず、前述するステアリン酸塩とショ糖脂肪酸エステルの比率等に応じて適宜設定される。例えば、ショ糖脂肪酸エステルの含有量として、当該造粒物の総量当たり、通常0.01〜20重量%、好ましくは0.1〜15重量%、より好ましくは0.5〜10重量%、更に好ましくは0.75〜10重量%が挙げられる。 When the sucrose fatty acid ester is contained in the granulated product of the present invention, the content of the sucrose fatty acid ester is not particularly limited, and is appropriately set according to the ratio of the stearate to the sucrose fatty acid ester described above. Is done. For example, the content of sucrose fatty acid ester is usually 0.01 to 20% by weight, preferably 0.1 to 15% by weight, more preferably 0.5 to 10% by weight, based on the total amount of the granulated product. Preferably 0.75 to 10 weight% is mentioned.
本発明の造粒物は、賦形剤を含有することもできる。本発明の造粒物に配合可能な賦形剤としては、薬学的に許容される限り特に制限されず、例えば、乳糖、ブドウ糖、麦芽糖、ショ糖、白糖等の糖類:マンニトール、ソルビトール、キシリトール、トレハロース、エリスリトール等の糖アルコール;トウモロコシデンプン、バレイショデンプン、小麦デンプン、米デンプン、α化デンプン、デキストリン、カルボキシメチルスターチ等のデンプン及びその誘導体;セルロース、結晶セルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロース等のセルロース及びその誘導体;アラビアガム、デキストラン、プルラン、軽質無水ケイ酸、合成ケイ酸アルミニウム、メタケイ酸アルミン酸マグネシウム、リン酸カルシウム、炭酸カルシウム、硫酸カルシウム、クロスポビドン、クロスカルメロースナトリウム、カルメロースカルシウム等が挙げられる。これらの賦形剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。これらの賦形剤の中でも、好ましくは糖類、更に好ましくは乳糖が挙げられる。 The granulated product of the present invention can also contain an excipient. The excipient that can be blended in the granulated product of the present invention is not particularly limited as long as it is pharmaceutically acceptable. For example, sugars such as lactose, glucose, maltose, sucrose, and sucrose: mannitol, sorbitol, xylitol, Sugar alcohols such as trehalose and erythritol; starches such as corn starch, potato starch, wheat starch, rice starch, pregelatinized starch, dextrin, carboxymethyl starch and derivatives thereof; cellulose, crystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxy Cellulose and its derivatives such as methylcellulose; gum arabic, dextran, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminate metasilicate, calcium phosphate, calcium carbonate, Calcium, crospovidone, croscarmellose sodium, carmellose calcium, and the like. These excipients may be used alone or in combination of two or more. Among these excipients, saccharides are preferable, and lactose is more preferable.
本発明の造粒物に賦形剤を含有させる場合、当該賦形剤の含有量については、特に制限されないが、例えば、当該造粒物の総量当たり、通常5〜75重量%、好ましくは10〜50重量%、更に好ましくは15〜40重量%が挙げられる。 When the granulated product of the present invention contains an excipient, the content of the excipient is not particularly limited. For example, it is usually 5 to 75% by weight, preferably 10%, based on the total amount of the granulated product. -50% by weight, more preferably 15-40% by weight.
また、本発明の造粒物は、必要に応じて、更に、崩壊剤、滑沢剤、結合剤、保存剤、酸味料、甘味料、香料、着色料等を含有してもよい。 In addition, the granulated product of the present invention may further contain a disintegrant, a lubricant, a binder, a preservative, a sour agent, a sweetener, a fragrance, a colorant, and the like as necessary.
本発明の造粒物の平均粒径については、特に制限されないが、例えば、100〜2000μm、好ましくは250〜1500μm、更に好ましくは300〜1000μmが挙げられる。ここで、造粒物の平均粒径とは、第15改正日本薬局方の粒度測定法のふるい分け法に準じて行う際の積算50重量%の粒子径である。 Although it does not restrict | limit especially about the average particle diameter of the granulated material of this invention, For example, 100-2000 micrometers, Preferably it is 250-1500 micrometers, More preferably, 300-1000 micrometers is mentioned. Here, the average particle size of the granulated product is a particle size of 50% by weight when performing according to the screening method of the particle size measurement method of the 15th revision Japanese Pharmacopoeia.
本発明の造粒物の製造は、例えば、乾式造粒法、加熱造粒等の造粒法によって行うことができる。これらの造粒法の中でも、熱負荷が少なく、本発明の造粒物の成形性を高め、効率的な製造を行うには、乾式造粒法(特に、ローラーコンパクターを用いた乾式造粒法)が好適である。 The granulated product of the present invention can be produced, for example, by a granulation method such as a dry granulation method or a heat granulation method. Among these granulation methods, the dry granulation method (especially, the dry granulation method using a roller compactor is used to reduce the heat load, improve the moldability of the granulated product of the present invention, and perform efficient production. ) Is preferred.
本発明の造粒物は、そのまま顆粒剤又は細粒剤として提供することができるが、必要に応じて、水溶性高分子等によりコーティングを施してコーティング製剤として提供したり、カプセルに充填してカプセル剤として提供することもできる。更に、本発明の造粒物は、更に打錠成型に供して錠剤として提供してもよい。 The granulated product of the present invention can be provided as it is as a granule or a fine granule, but if necessary, it can be provided as a coating preparation by coating with a water-soluble polymer or filled into a capsule. It can also be provided as a capsule. Furthermore, the granulated product of the present invention may be further provided for tableting by tableting.
本発明の造粒物は、下肢の筋力低下、神経痛、関節の腫れや痛み、関節リウマチ、関節炎等を改善するための漢方製剤として使用される。 The granulated product of the present invention is used as a Chinese medicine preparation for improving lower extremity muscle weakness, neuralgia, joint swelling and pain, rheumatoid arthritis, arthritis and the like.
本発明の造粒物を含む漢方製剤は、1日当たり、加味四物湯エキス末の乾燥エキス量換算で1000〜6000mg1日当たり1回又は数回に分けて経口投与することができ、その投与量は、年齢、体重、症状の程度等に応じて適宜調整することができる。 The Kampo preparation containing the granulated product of the present invention can be orally administered per day or divided into 1000 to 6000 mg per day in terms of the dry extract amount of Kamishitokuto extract powder. , Age, weight, symptom degree, etc. can be adjusted as appropriate.
以下に、実施例等に基づいて本発明を詳細に説明するが、本発明はこれらによって限定されるものではない。 Hereinafter, the present invention will be described in detail based on examples and the like, but the present invention is not limited thereto.
試験例1
1.加味四物湯エキス末の製造
当帰3重量部、川きゅう3重量部、芍薬3重量部、地黄3重量部、蒼朮3重量部、麦門冬5重量部、人参2.5重量部、牛膝2.5重量部、黄柏1.5重量部、五味子1.5重量部、黄連1、5重量部、知母1.5重量部、及び杜仲1.5重量部の割合でとり、10倍量の水を用いて、約1時間加熱抽出を行った。得られた抽出液をろ過にて回収した。
Test example 1
1. Manufacture of Kamitsumonoyu extract powder 3 parts by weight, 3 parts by weight of river cucumber, 3 parts by weight of glaze, 3 parts by weight of ground yellow, 3 parts by weight of straw, 5 parts by weight of Mumon winter, 2.5 parts by weight of carrot, beef 10 parts by weight of 2.5 parts by weight of the knee, 1.5 parts by weight of jaundice, 1.5 parts by weight of gouriko, 1, 5 parts by weight of the yellow chain, 1.5 parts by weight of the mother, and 1.5 parts by weight of Tonaka. Heat extraction was performed for about 1 hour using double amount of water. The obtained extract was collected by filtration.
得られた抽出液を70℃以下で減圧濃縮後、賦形剤を適当量添加して、スプレードライにより乾燥させて、加味四物湯エキス末(加味四物湯の乾燥エキス量70重量%、賦形剤30重量%含有)を得た。 The obtained extract was concentrated under reduced pressure at 70 ° C. or lower, added with an appropriate amount of excipient, dried by spray drying, and added to Kamitsutoyu extract powder (70% by weight of dry extract of Kamijotoyu, 30% by weight of excipient) was obtained.
2.造粒物の製造
上記で得られた加味四物湯エキス末、ステアリン酸マグネシウム、及び乳糖を、表1に示す割合で混合して、ローラーコンパクター(フロイント産業株式会社製)で圧縮成形した後に、ロールグラニュレーターを用いて粉砕することにより顆粒を得た。得られた顆粒の平均粒径は600〜900μmであった。
2. Manufacture of granulated product After mixing the Kamitsuyuto extract powder obtained above, magnesium stearate, and lactose in the proportions shown in Table 1, compression molding with a roller compactor (Freund Sangyo Co., Ltd.) Granules were obtained by grinding using a roll granulator. The average particle diameter of the obtained granules was 600 to 900 μm.
3.成形性及び崩壊性の評価
上記の顆粒製造時に、ローラーコンパクターのロールへの原料の付着の程度を目視にて観察し、下記の判定基準に従って、成形性を評価した。
<成形性の判定基準>
5:ロールへの原料の付着が全く認められず、圧縮成形・粉砕を全く問題なく行うことができた。
4:ロールに原料が僅かに付着していたが、圧縮成形に殆ど影響がなく、圧縮成形・粉砕を問題なく行うことができた。
3:ロールに原料が付着し、圧縮成形時に製造ロスを生じ、ローラーコンパクターによる圧縮成形物の製造効率が低下したが、圧縮成形・粉砕は行うことができた。
2:ロールへの原料の付着量が多く、時間の経過と共に、ローラーコンパクターによる圧縮成形物の製造効率が低下していき、最終的には、全ての原料を圧縮成形物にすることができなかった。
1:ロールへの原料の付着が顕著であり、ローラーコンパクターによる圧縮成形物を製造できなかった。
3. Evaluation of moldability and disintegration At the time of granule production, the degree of adhesion of the raw material to the roll of the roller compactor was visually observed, and the moldability was evaluated according to the following criteria.
<Criteria for moldability>
5: Adhesion of the raw material to the roll was not recognized at all, and compression molding / pulverization could be performed without any problem.
4: The raw material was slightly attached to the roll, but there was almost no influence on compression molding, and compression molding / pulverization could be performed without any problem.
3: The raw material adhered to the roll, resulting in production loss during compression molding, and the production efficiency of the compression molded product by the roller compactor was reduced, but compression molding / pulverization could be performed.
2: The amount of raw material attached to the roll is large, and over time, the production efficiency of the compression molded product by the roller compactor decreases, and finally, all the raw materials cannot be made into a compression molded product. It was.
1: The adhesion of the raw material to the roll was remarkable, and a compression molded product with a roller compactor could not be produced.
更に、上記で得られた顆粒について、第16改正日本薬局方の崩壊試験法に準じて、崩壊性の評価を行った。具体的には、30号篩に残留した顆粒を0.10gずつ補助筒に入れ、試験液として37±2℃の水を用いて試験機を作動させ、崩壊した時間を測定した。 Further, the granules obtained above were evaluated for disintegration according to the 16th revised Japanese Pharmacopoeia disintegration test method. Specifically, 0.10 g of the granules remaining on the No. 30 sieve were put in an auxiliary cylinder, the test machine was operated using water at 37 ± 2 ° C. as a test solution, and the collapse time was measured.
4.結果
得られた結果を表1に示す。表1から明らかなように、ステアリン酸マグネシウムを配合せずに造粒した場合(比較例1)では、成型性が著しく悪く、顆粒の製造ができなかったが、ステアリン酸マグネシウムを配合して造粒した場合(実施例1−5)では、成型性が向上しており、高い製造効率で顆粒を製造することができた。とりわけ、ステアリン酸マグネシウムの含有量が2重量%以上、特に2.5〜4重量%の場合に、成形性が顕著に優れていた。また、ステアリン酸マグネシウムを配合した顆粒(実施例1−5)は、いずれも、崩壊時間が30分以内であり、良好な崩壊性を備えていることも確認された。
4). Results The results obtained are shown in Table 1. As is apparent from Table 1, when granulation was performed without blending magnesium stearate (Comparative Example 1), the moldability was remarkably poor and the granule could not be produced. In the case of granulation (Example 1-5), the moldability was improved, and granules could be produced with high production efficiency. In particular, when the content of magnesium stearate was 2% by weight or more, particularly 2.5 to 4% by weight, the moldability was remarkably excellent. Moreover, it was also confirmed that the granule (Example 1-5) which mix | blended magnesium stearate has disintegration time within 30 minutes and is equipped with favorable disintegration property.
また、実施例3において、ステアリン酸マグネシウムに代えて、ステアリン酸カルシウム、又はステアリン酸アルミニウムを使用して顆粒を調製したところ、同様に成形性及び崩壊性に優れた顆粒を得ることができた。但し、成形性及び崩壊性は、ステアリン酸マグネシウムを配合した顆粒が、特に優れていた。
一方、実施例3において、ステアリン酸マグネシウムに代えてタルクを使用して顆粒を調製したところ、成形性及び崩壊性ともに優れた顆粒を得ることはできなかった。
In Example 3, when granules were prepared using calcium stearate or aluminum stearate instead of magnesium stearate, granules excellent in moldability and disintegration could be obtained. However, in terms of moldability and disintegration, the granules containing magnesium stearate were particularly excellent.
On the other hand, when granules were prepared using talc instead of magnesium stearate in Example 3, it was not possible to obtain granules excellent in both moldability and disintegration.
試験例2
試験例1で調製した加味四物湯エキス末、ステアリン酸マグネシウム、ショ糖ステアリン酸エステル及び乳糖を、表2に示す割合で混合して、ローラーコンパクター(フロイント産業株式会社製)で圧縮成形した後に、ロールグラニュレーターを用いて粉砕することにより顆粒を得た。得られた顆粒の平均粒径は600〜950μmであった。顆粒製造時の成形性、及び顆粒の崩壊性について、試験例1と同様の方法で評価を行った。
Test example 2
After mixing the Kamitsumonoyu extract powder, magnesium stearate, sucrose stearate and lactose prepared in Test Example 1 in the proportions shown in Table 2, and compression-molding with a roller compactor (Freund Sangyo Co., Ltd.) Granules were obtained by grinding using a roll granulator. The average particle diameter of the obtained granules was 600 to 950 μm. The moldability during granule production and the disintegration property of the granules were evaluated by the same method as in Test Example 1.
得られた結果を表2に示す。この結果から、加味四物湯エキス末及びステアリン酸マグネシウムに加えて、ショ糖ステアリン酸エステルを配合することによって、優れた成形性を維持しつつ、崩壊性をより一層向上できることが確認された(実施例6−13)。とりわけ、ステアリン酸マグネシウム1重量部当たり、ショ糖ステアリン酸エステルが0.166〜4重量部、特に0.25〜3重量部の比率で含まれている場合には、崩壊性が格段顕著に向上することが明らかとなった。 The obtained results are shown in Table 2. From this result, it was confirmed that by adding sucrose stearate in addition to the Kamitsumonoyu extract powder and magnesium stearate, the disintegration property can be further improved while maintaining excellent moldability ( Example 6-13). In particular, when sucrose stearate is contained at a ratio of 0.166 to 4 parts by weight, particularly 0.25 to 3 parts by weight per 1 part by weight of magnesium stearate, the disintegration is remarkably improved. It became clear to do.
試験例3
試験例1で調製した加味四物湯エキス末、ステアリン酸マグネシウム、表3に示す各種ショ糖脂肪酸エステル及び乳糖を、表3に示す割合で混合して、ローラーコンパクター(フロイント産業社製)で圧縮成形した後に、ロールグラニュレーターを用いて粉砕することにより顆粒を得た。得られた顆粒の平均粒径は500〜900μmであった。顆粒製造時の成形性、及び顆粒の崩壊性について、試験例1と同様の方法で評価を行った。
Test example 3
Kamijotsuyu extract powder prepared in Test Example 1, magnesium stearate, various sucrose fatty acid esters and lactose shown in Table 3 were mixed at the ratio shown in Table 3, and compressed with a roller compactor (Freund Sangyo Co., Ltd.). After molding, granules were obtained by grinding using a roll granulator. The average particle diameter of the obtained granules was 500 to 900 μm. The moldability during granule production and the disintegration property of the granules were evaluated by the same method as in Test Example 1.
得られた結果を表3に示す。この結果から、ショ糖脂肪酸エステルを構成する脂肪酸の炭素数を変化させても、上記試験例2の結果と同様に、崩壊性をより一層向上させ得ることが確認された。特に、本結果から、ショ糖脂肪酸エステルの構成脂肪酸の炭素数が16〜18である場合やショ糖脂肪酸エステルのHLB値が11以上である場合(実施例15、16及び18)に、格段顕著に崩壊性を向上させ得ることも確認された。 The obtained results are shown in Table 3. From this result, it was confirmed that even when the carbon number of the fatty acid constituting the sucrose fatty acid ester was changed, the disintegration property could be further improved as in the result of Test Example 2. In particular, from this result, when the number of carbon atoms of the constituent fatty acid of the sucrose fatty acid ester is 16 to 18 or when the HLB value of the sucrose fatty acid ester is 11 or more (Examples 15, 16 and 18), it is remarkably remarkable. It was also confirmed that the disintegration property can be improved.
処方例
下記表4〜6に、本発明の造粒物に関する処方例1〜18を示す。試験例1で調製した加味四物湯エキス末を用いて、常法により、処方例1〜18に示す組成の造粒物を製した。これらの造粒物についても試験例1と同様の試験を実施したところ、製造時の成形性に優れ、良好な崩壊性を有することが確認された。
Formulation Examples Tables 4 to 6 below show Formulation Examples 1 to 18 relating to the granulated product of the present invention. A granulated product having the composition shown in Formulation Examples 1 to 18 was prepared by a conventional method using the Kamitsuyumono extract powder prepared in Test Example 1. When these granules were subjected to the same test as in Test Example 1, it was confirmed that the granules were excellent in moldability during production and had good disintegration properties.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011214749A JP6195428B2 (en) | 2011-09-29 | 2011-09-29 | Granulated product containing Kamitsumonoyu extract powder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011214749A JP6195428B2 (en) | 2011-09-29 | 2011-09-29 | Granulated product containing Kamitsumonoyu extract powder |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016196231A Division JP6272432B2 (en) | 2016-10-04 | 2016-10-04 | Granulated product containing Kamitsumonoyu extract powder |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013071935A true JP2013071935A (en) | 2013-04-22 |
JP6195428B2 JP6195428B2 (en) | 2017-09-13 |
Family
ID=48476703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011214749A Active JP6195428B2 (en) | 2011-09-29 | 2011-09-29 | Granulated product containing Kamitsumonoyu extract powder |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6195428B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784308A (en) * | 2014-01-20 | 2015-07-22 | 孟宪铎 | Externally applied medicine for detoxifying, eliminating swelling and removing blood stasis to treat traumatic injury |
CN105031213A (en) * | 2015-08-11 | 2015-11-11 | 旷琼燕 | Traditional Chine medicine foot bathing powder for treating arthritis and preparation method thereof |
CN105343603A (en) * | 2015-11-23 | 2016-02-24 | 王维化 | Physiotherapy medicine package for treating prosopalgia and preparation method thereof |
CN106256362A (en) * | 2016-09-28 | 2016-12-28 | 四川易创生物科技有限公司 | One can effectively treat neurasthenic endo-medicine and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5936621A (en) * | 1982-08-25 | 1984-02-28 | Tsumura Juntendo Inc | Improving agent for cancerous symptom |
JPS5936620A (en) * | 1982-08-24 | 1984-02-28 | Tsumura Juntendo Inc | Carcinostatic adjuvant |
JPH05194246A (en) * | 1991-09-05 | 1993-08-03 | Tsumura & Co | Production of herb medicinal hard capsule |
JPH0789875A (en) * | 1993-09-20 | 1995-04-04 | Dai Ichi Seiyaku Co Ltd | Tablet free from disintegration delay |
JPH07112927A (en) * | 1993-10-13 | 1995-05-02 | Tsumura & Co | Production of capsule of herb medicine |
JPH09253171A (en) * | 1996-03-25 | 1997-09-30 | Sho Takemori | Chinese medicine pill |
-
2011
- 2011-09-29 JP JP2011214749A patent/JP6195428B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5936620A (en) * | 1982-08-24 | 1984-02-28 | Tsumura Juntendo Inc | Carcinostatic adjuvant |
JPS5936621A (en) * | 1982-08-25 | 1984-02-28 | Tsumura Juntendo Inc | Improving agent for cancerous symptom |
JPH05194246A (en) * | 1991-09-05 | 1993-08-03 | Tsumura & Co | Production of herb medicinal hard capsule |
JPH0789875A (en) * | 1993-09-20 | 1995-04-04 | Dai Ichi Seiyaku Co Ltd | Tablet free from disintegration delay |
JPH07112927A (en) * | 1993-10-13 | 1995-05-02 | Tsumura & Co | Production of capsule of herb medicine |
JPH09253171A (en) * | 1996-03-25 | 1997-09-30 | Sho Takemori | Chinese medicine pill |
Non-Patent Citations (4)
Title |
---|
JPN6015035436; 薬学用語解説「滑沢剤」 , 2007 * |
JPN6015035439; 医薬品製剤化方略と新技術 第1刷, 2007, pp.335-340, 株式会社シーエムシー出版 * |
JPN6015035441; リウマチ Vol.41 No.2, 2001, p.388 * |
JPN6016008643; 医薬品添加物事典 第1刷, 2007, pp.151-153 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784308A (en) * | 2014-01-20 | 2015-07-22 | 孟宪铎 | Externally applied medicine for detoxifying, eliminating swelling and removing blood stasis to treat traumatic injury |
CN105031213A (en) * | 2015-08-11 | 2015-11-11 | 旷琼燕 | Traditional Chine medicine foot bathing powder for treating arthritis and preparation method thereof |
CN105343603A (en) * | 2015-11-23 | 2016-02-24 | 王维化 | Physiotherapy medicine package for treating prosopalgia and preparation method thereof |
CN106256362A (en) * | 2016-09-28 | 2016-12-28 | 四川易创生物科技有限公司 | One can effectively treat neurasthenic endo-medicine and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP6195428B2 (en) | 2017-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9592199B2 (en) | Cellulose powder | |
US11390690B2 (en) | Cellulose powder | |
JP6272432B2 (en) | Granulated product containing Kamitsumonoyu extract powder | |
JP6195428B2 (en) | Granulated product containing Kamitsumonoyu extract powder | |
TWI714536B (en) | Disintegrable particle composition containing crushed lactose or granulated lactose | |
JPWO2015115453A1 (en) | Oral rapidly disintegrating composition for solid preparation | |
CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
WO2008136636A1 (en) | Composition for fast disintegrating tablet containing herbal extract and its preparation method | |
CN1895535A (en) | Chinese-medicinal preparation for treating gutture disease and it making method | |
CN102100902B (en) | Counterflow effervescent tablets | |
CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
JP6262490B2 (en) | Intraoral rapidly disintegrating tablet composition | |
JP6407545B2 (en) | Pharmaceutical composition | |
TWI781921B (en) | Dry granulated material and solid preparation containing dry granulated material and method for producing the same | |
Nnamani et al. | Dry Granule Formulation For Ciprofloxacin Hydrochloride Capsule Using Co-Processed< i> Grewia Mollis< i> Gum | |
JPH02152926A (en) | Brain edema depressant | |
CN106138226A (en) | A kind of Chinese medicine granules preventing and treating porcine hyperthermia and preparation method thereof | |
JP2001181195A (en) | Solid preparation containing tetousutore extract as active ingredient | |
JP2021172614A (en) | Method for producing chinese herbal extract preparation | |
CN100441209C (en) | 'Weitongning' dispersing tablets prepn. for treating stomach trouble and its prepn. method | |
Kamble et al. | Preparation of Tablet from Naagdon Plant by Wet Granulation Method for Treatment of Excessive Bleeding in Piles | |
Adriany et al. | Formulation of orodispersible tablet of luffa acutangula (L) roxb using novel co-processed via spray dried excipient | |
JP6927763B2 (en) | Tablets containing Seihaito extract powder | |
JP7114227B2 (en) | Tablets containing Seihaito extract powder | |
CN105287931A (en) | Compound honeysuckle flower anti-cold dispersible tablets and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160502 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161004 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20161121 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170815 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6195428 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |